Publications

Plasma proteoforms of apolipoproteins C-I and C-II are associated with plasma lipids in the Multi-Ethnic Study of Atherosclerosis. J. Lipid Res. 63 100263, 2022.
Distinct patterns of apolipoprotein C-I, C-II and C-III isoforms are associated with markers of Alzheimer's disease. J. Lipid Res. 62, 100014, 2021.
Simple and Fast Assay for Apolipoprotein E Phenotyping and Glycotyping: Discovering Isoform-Specific Glycosylation in Plasma and Cerebrospinal Fluid. J. Alzheimer's Dis. 76 (2020) 883-893.
Complexity, cost, and content - three important factors for translation of clinical protein mass spectrometry tests, and the case for apolipoprotein C-III proteoform testing, Clin Chem Lab Med. 2020 Jun 25;58(6):858-863.
ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors, Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):2145-2156.

An association of CSF apolipoprotein E glycosylation and amyloid-beta 42 in individuals who carry the APOE4 allele, AD/PD 2023, Advances in Science & Therapy, Gothenburg, Sweden, March 25-April 1, 2023.
Lower CSF ApoE Glycosylation Associates with Measures of Alzheimer’s Disease Biomarkers, Alzheimer's Association International Conference AAIC 2022, San Diego, CA, July 31 - August 4, 2022.
Discovering Apolipoprotein E isoform-Specific Glycosylation, and Its Implication in Alzheimer’s Disease Pathology, 36th Asilomar Conference on Mass Spectrometry: The role of mass spectrometry in neurodegenarative disease research, December 10-14, 2021.
Distinct patterns of apolipoprotein C-I, C-II and C-III isoforms are associated with markers of Alzheimer's disease, 69th ASMS Conference, Philadelphia, PA, Oct 31-Nov. 4, 2021.
Mass spectrometric immunoassay for detection of isoform-specific apolipoprotein E glycosylation, 2021 AACC Annual Meeting, Atlanta, GA, Sep. 26-30, 2021.